CTLA4 and cancer: In addition to PD-1, another combination therapy with EGFRvIII-directed CAR T cell engineered to express anti-CTLA-4 and PD-1 antibodies, is in the second phase I/II clinical trial (NCT03182816), showing improved persistence and activity of T cells in its cancer killing capacity (28).